{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:31:28Z","timestamp":1790188288822,"version":"4.1.0"},"reference-count":79,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Peripheral Nervous Sys"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:p><jats:bold>Abstract\u2003<\/jats:bold> Peripheral neurological disorders like neuropathies may cause impairments (such as weakness and sensory deficits), which may lead to problems in daily life and social functioning with a possible decrement in quality of life expectations. Choosing the proper outcome measure to evaluate the therapeutic efficacy of an intervention at one of these levels of outcome should therefore be considered as fundamental to the design of randomized trials in peripheral neurological disorders. However, these choices are dependent not only on the proposed research purposes but also, and perhaps more importantly, on the fulfillment of the scientific needs of these measures. With an increasing demand for accuracy, a thorough and comprehensive evaluation of an outcome measure is needed to determine its simplicity, communicability, validity, reliability, and responsiveness before being clinically applicable, techniques that are being captured by the science of clinimetrics. Most neurologists are still unfamiliar with these rigorous methodological essentials or overlook some of them in their trial preparations because these are considered time consuming and mind numbing. This review will highlight, against the background of the international classification framework and clinimetric needs for outcome measures, the selected scales applied in published randomized controlled trials in patients with Guillain\u2010Barr\u00e9 syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, and gammopathy\u2010related neuropathies. The need for comparison responsiveness studies between equally valid and reliable measures and to standardize their use is emphasized in these conditions. Finally, specific recommendations are given to move from classic to modern clinimetric approach when constructing, evaluating, and selecting outcome measures using new methods like Rasch analysis, accentuating the need of shifting toward a more modern era.<\/jats:p>","DOI":"10.1111\/j.1529-8027.2008.00169.x","type":"journal-article","created":{"date-parts":[[2008,6,30]],"date-time":"2008-06-30T15:22:14Z","timestamp":1214839334000},"page":"136-147","source":"Crossref","is-referenced-by-count":39,"title":["Outcome measures in immune\u2010mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials"],"prefix":"10.1111","volume":"13","author":[{"given":"Sonja I.","family":"Van Nes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina G.","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingemar S. J.","family":"Merkies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"69","article-title":"Quality of life: what is it? How should it be measured?","volume":"2","author":"Aaronson NK","year":"1988","journal-title":"Oncology"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000103528.48582.7c"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/apmr.2003.50247"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4324\/9781410600127","volume-title":"Applying the Rasch Model: Fundamental Measurement for the Human Sciences","author":"Bond TG","year":"2001"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.1.100"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-002-0808-z"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410400516"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.35.8.1173"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199111213252105"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.6.799"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000149522.32823.EA"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.37.5.837"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.9.1256"},{"key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/j.ctt1xp3vbc","volume-title":"Clinimetrics","author":"Feinstein AR","year":"1987"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta2140"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410220612"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410304"},{"issue":"1012","key":"e_1_2_8_20_1","first-page":"1416","article-title":"Treatment of Guillain\u2010Barr\u00e9 syndrome with mycophenolate mofetil: a pilot study","volume":"78","author":"Garssen MP","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.046227"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2005.081547"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)91341-2"},{"key":"e_1_2_8_24_1","first-page":"586","article-title":"Double\u2010blind trial of intravenous methylprednisolone in Guillain\u2010Barr\u00e9 syndrome","volume":"341","author":"Guillain\u2010Barr\u00e9 Syndrome Steroid Trial Group","year":"1993","journal-title":"Lancet"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.35.8.1096"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365549509019016"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.1.57"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/119.4.1067"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/119.4.1055"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(95)00357-8"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200009002-00007"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.60.2.127"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb11015.x"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1088"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)92644-2"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70329-0"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-198903001-00015"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880141111"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15324-X"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-1324"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/124.1.145"},{"key":"e_1_2_8_42_1","first-page":"1191","article-title":"Evaluating measurement responsiveness","volume":"22","author":"Liang MH","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199007000-00008"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000044402.16315.FC"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2007.08.004"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.63.1.28"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006324-200208000-00015"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204233261705"},{"key":"e_1_2_8_49_1","first-page":"1","volume-title":"Her Majesty\u2019s Stationery Office","author":"Medical Research Council","year":"1943"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.35.11.1551"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.4.445"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.8.1648"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4598(200009)23:9<1393::AID-MUS10>3.0.CO;2-O"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.1.84"},{"key":"e_1_2_8_55_1","unstructured":"MerkiesISJ(2001).Evaluation of scales and measurement instruments in immune\u2010mediated polyneuropathies[thesis].Erasmus Medical Centre Rotterdam The Netherlands. ISBN: 90\u20109014393\u20109."},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2005.12.003"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.4.943"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.72.5.596"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000265055.28218.cc"},{"key":"e_1_2_8_60_1","first-page":"69","article-title":"A randomized controlled trial comparing intravenous immunoglobulin and plasmapheresis in Guillain\u2010Barr\u00e9 syndrome","volume":"18","author":"Nomura T","year":"2001","journal-title":"Neurol Ther"},{"key":"e_1_2_8_61_1","first-page":"244","volume-title":"Psychometric Theory","author":"Nunnally JC","year":"1978"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.59.3.243"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)90819-5"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200212000-00046"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm144"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09095-2"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000092019.53628.88"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.71.2.235"},{"key":"e_1_2_8_69_1","first-page":"128","article-title":"Double blind control trial of prednisolone in Guillain\u2010Barr\u00e9 syndrome \u2013 a clinical study","volume":"52","author":"Shukla SK","year":"1988","journal-title":"Clin India"},{"key":"e_1_2_8_70_1","first-page":"22","article-title":"Do corticosteroids influence the disease course or mortality in Guillain\u2010Barr\u00e9 syndrome","volume":"44","author":"Singh NK","year":"1996","journal-title":"J Assoc Physicians India"},{"key":"e_1_2_8_71_1","volume-title":"A Practical Guide to Their Development and Use","author":"Streiner DL","year":"1998"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.26.3.205"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.59.3.248"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.2.209"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.56.1.36"},{"key":"e_1_2_8_76_1","first-page":"223","article-title":"Intravenous immunoglobulin in children with Guillain\u2010Barr\u00e9 syndrome","volume":"16","author":"Wang R","year":"2001","journal-title":"J Appl Clin Pediatr"},{"key":"e_1_2_8_77_1","volume-title":"SF\u201036 Health Survey Manual and Interpretation Guide","author":"Ware JE","year":"1997"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.5.774"},{"key":"e_1_2_8_79_1","first-page":"7","volume-title":"International Classification of Impairments, Disabilities, and Handicaps","author":"World Health Organization","year":"1980"},{"key":"e_1_2_8_80_1","first-page":"3","volume-title":"International Classification of Functioning, Disability, and Health","author":"World Health Organization","year":"2001"}],"container-title":["Journal of the Peripheral Nervous System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1529-8027.2008.00169.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1529-8027.2008.00169.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T20:35:28Z","timestamp":1697142928000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1529-8027.2008.00169.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1111\/j.1529-8027.2008.00169.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1529-8027.2008.00169.x","archive":["Portico"],"relation":{},"ISSN":["1085-9489","1529-8027"],"issn-type":[{"value":"1085-9489","type":"print"},{"value":"1529-8027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}